Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBITDA Margin: 2021-2024

Historic EBITDA Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to -10.25%.

  • Kiniksa Pharmaceuticals International's EBITDA Margin rose 2137.00% to 10.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.99%, marking a year-over-year increase of 836.00%. This contributed to the annual value of -10.25% for FY2024, which is 1544.00% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported EBITDA Margin of -10.25% as of FY2024, which was down 297.13% from 5.20% recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's EBITDA Margin ranged from a high of 1,834.73% in FY2022 and a low of -409.81% during FY2021.
  • For the 3-year period, Kiniksa Pharmaceuticals International's EBITDA Margin averaged around 609.89%, with its median value being 5.20% (2023).
  • Its EBITDA Margin has fluctuated over the past 5 years, first spiked by 224,454bps in 2022, then slumped by 182,953bps in 2023.
  • Over the past 4 years, Kiniksa Pharmaceuticals International's EBITDA Margin (Yearly) stood at -409.81% in 2021, then spiked by 224,454bps to 1,834.73% in 2022, then plummeted by 182,953bps to 5.20% in 2023, then tumbled by 1,544bps to -10.25% in 2024.